Trials / Unknown
UnknownNCT05911984
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (estimated)
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a single ascending dose study of 9MW3811, the primary objective of which is to evaluate the safety, tolerability and preliminary efficacy of 9MW3811 in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 9MW3811 Injection | Intravenous injection |
Timeline
- Start date
- 2023-06-30
- Primary completion
- 2024-03-01
- Completion
- 2024-03-01
- First posted
- 2023-06-22
- Last updated
- 2023-06-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05911984. Inclusion in this directory is not an endorsement.